Key result
Intravenous immunoglobulin did not prevent the recurrence of congenital heart block, with 3 cases (15%) occurring among 20 treated pregnancies, reaching the predetermined stopping rule.
Why the study?
Does intravenous immunoglobulin (IVIG) prevent the development of second-degree or third-degree congenital heart block in high-risk pregnant women?
Population
20 pregnant women with anti-SSA/Ro antibodies, a previous child with congenital heart block or neonatal…
Design
Cohort, open-label
Follow-up
until delivery
Authors
Loading...
IVIG should not yet inform practice for recurrent CHB prevention; leaves open the need for alternative strategies in anti-SSA/Ro pregnancies.
Does intravenous immunoglobulin (IVIG) prevent the development of second-degree or third-degree congenital heart block in high-risk pregnant women?
Low-dose intravenous immunoglobulin (400 mg/kg) during pregnancy does not prevent the recurrence of congenital heart block in high-risk mothers.
Friedman et al. (2010) studied congenital heart block (CHB) (n=20). intravenous immunoglobulin (IVIG) was evaluated on development of second-degree or third-degree CHB. Intravenous immunoglobulin did not prevent the recurrence of congenital heart block, with 3 cases (15%) occurring among 20 treated pregnancies, reaching the predetermined stopping rule.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: